香青兰滴丸对冠脉结扎诱发大鼠急性心肌缺血的保护作用

目的 研究香青兰滴丸对大鼠急性心肌缺血损伤的保护作用,并与现有制剂进行对比.方法 结扎大鼠冠状动脉左前降支致急性心肌缺血模型,术后每天给予香青兰滴丸1次,连续给药5d,采用Ⅱ导心电图(ECGⅡ)测心肌损伤程度;心脏用红四氮唑(TTC)染色测定心肌梗死范围;试剂盒法测定血清中天冬氨酸氨基转移酶(AST)、乳酸脱氢酶(LDH)和肌酸磷酸激酶同工酶(CK-MB)的活性.结果 4.8、9.6 g/kg香青兰滴丸可以显著改善大鼠心肌缺血损伤,减小心肌梗死范围,分别减少了30.3％ (P＜0.01)、53.3％ (P＜0.001),降低AST、LDH和CK-MB的活性.与等剂量益心巴迪然吉布亚颗粒比较,香青兰滴丸对心肌梗死大鼠的各项测定指标差异均无显著性.结论 香青兰滴丸对大鼠急性心肌缺血损伤具有一定的保护作用,其疗效与益心巴迪然吉布亚颗粒相近.     

HPLC-PDA法检测正天丸和正天胶囊中6种非法添加色素

目的建立HPLC-PDA法测定正天丸和正天胶囊非法添加色素胭脂红、日落黄、诱惑红、赤鲜红、酸性红73、金橙Ⅱ的方法。方法样品用70%乙醇提取,以乙腈-0.02mol/L醋酸铵梯度洗脱,PDA检测器检测。结果 8批正天丸和4批正天胶囊均未检出有胭脂红、日落黄、诱惑红、赤藓红、酸性红73、金橙Ⅱ。结论本实验采用HPLC-PDA法检测正天丸和正天胶囊中6种非法添加色素,方法简单、准确、快速、重复性好,可为评价正天丸、正天胶囊的质量提供一定的参考。     

阿卡波糖联合六味地黄丸治疗早期糖尿病肾病的临床疗效观察

目的 观察六味地黄丸对早期糖尿病肾病患者的临床疗效及其安全性。方法 选择天津市滨海新区大港港西街社区卫生服务中心2010年4月—2013年4月收治的早期糖尿病肾病患者72例,随机分为治疗组（36例）和对照组（36例）,对照组给予饮食及运动疗法,同时用阿卡波糖治疗,餐前服用,100 mg/次,3 次/d;治疗组在对照组治疗的基础上加用六味地黄丸治疗,6 g/次,2 次/d。治疗两个月后,比较两组患者24 h尿蛋白、血糖、血脂及尿微量白蛋白的变化,同时观察两组不良反应的发生情况。结果 两组患者治疗前后24 h尿蛋白、血糖、血脂及尿微量白蛋白自身对照有明显差异（P＜0.05）;治疗组患者各项指标改善明显优于对照组（P＜0.05）,两组患者不良反应发生情况比较差异没有统计学意义。结论 阿卡波糖联合六味地黄丸治疗对于早期糖尿病肾病患者有较好的临床疗效,值得临床应用。     

西黄丸对荷瘤大鼠的抗肿瘤及其对炎性因子的调节作用

目的 研究西黄丸对Walker256乳腺癌细胞荷瘤大鼠的抗肿瘤及对相关炎性因子的调节作用,探讨其抗肿瘤作用机制。方法 60只雌性Wistar大鼠,随机抽取10只设为对照组,剩余50只建立荷瘤大鼠模型,随机分为模型组、西黄丸高、中、低剂量组和香菇多糖组,每组10只,按10 mL/kg ig给药,每天2次,连续14 d。14 d后腹主动脉取血,取瘤组织称定质量,计算抑瘤率;采用ELISA法检测大鼠外周血IL-2、IFN-γ、IL-6、IL-10和TGF-β水平。结果 西黄丸高、中、低剂量组抑瘤率分别为33.1%、30.7%、28.5%;与对照组比较,西黄丸高、中、低剂量均可明显提高荷瘤大鼠外周血IL-2、IFN-γ的水平,降低IL-6、IL-1、GF-β水平（P＜0.05）。结论 西黄丸具有明显的抑制肿瘤生长的作用,可通过提高荷瘤大鼠IL-2、IFN-γ水平增强免疫清除功能;降低IL-6、IL-10、TGF-β水平,减少形成免疫抑制微环境的相关炎性因子,呈现出逆转肿瘤免疫逃逸的趋势。     

犀黄丸对火毒血瘀型鼻咽癌放射治疗患者生活质量的影响

目的 观察犀黄丸对火毒血瘀型鼻咽癌放射治疗患者生活质量的影响。方法 将60例鼻咽癌患者随机分为实验组和对照组，每组30例。对照组仅接受放射治疗，实验组加用犀黄丸口服。观察并比较两组患者治疗前后中医证候积分，比较两组患者生活质量改善情况及不良反应。结果 两组患者治疗后中医证候积分均显著降低（P<0.05），实验组中医证候积分下降程度大于对照组（P<0.05）；实验组患者生活质量的改善优于对照组（P<0.05）；实验组总不良反应率（50.00%）与对照组（73.33%）比较，差异无统计学意义（P>0.05）。结论 犀黄丸可改善鼻咽癌患者的临床症状，提高患者生活质量，减少放射治疗的不良反应。     

健骨丸结合局部热敷治疗踝关节骨折的疗效

目的:观察健骨丸结合局部热敷辅助常规内固定术治疗对踝关节骨折患者的疗效。方法:选取2016年1月至2017年12月广元市中医院收治的踝关节骨折患者141例作为研究对象，按照不同的治疗方案分为对照组(n=69)和观察组(n=72)。经过21 d的治疗，分析患者股转换标志物与血流变指标的变化。结果:经过治疗后2组患者中医证候积分、视觉模拟评分(VAS)、血液流变学指标、β-I型胶原羧基端肽（β-CTx）、N-端骨钙素（N-MID）、总Ⅰ型胶原氨基端延长肽（T-PINP）均较治疗前改善，其中观察组改善较对照组明显,差异有统计学意义（P<0.05）。结论:健骨丸结合局部热敷辅助常规外固定治疗对踝关节功能的恢复效果明显，大幅度减轻康复期患者伤口部位疼痛，对骨折所引起的骨质疏松与静脉血栓形成也起到了保护预防的作用。     

Quantifying and characterising multi-compartment compliance aid provision

BackgroundMedication compliance aids (MCAs) to support adherence lack evidence for cost-effectiveness yet a 2001 survey in England estimated 100,000 patients receiving an MCA whilst living in their home.Objective(s): To obtain a contemporary estimate of MCA provision by community pharmacies in England and describe factors influencing pharmacist decision-making regarding MCA initiation.MethodsA stratified random sample of two community pharmacies per county (n = 40) in England were surveyed by telephone and a more detailed postal survey sent to participants expressing an interest. Data were collected to determine magnitude of MCA provision and, professional and administrative factors influencing initiation were reported as percentage (95% confidence interval) respondents reporting a factor.ResultsAn estimated 273,529 MCAs are filled by community pharmacies in England with a median (IQR) of 20(10, 50) MCAs per pharmacy per month provided for patients living in their home. Practitioners' judgement of appropriateness for MCA initiation was reported by 51.3 ± 11% as the primary factor influencing decision-making relative to 16.3 ± 8% and 20 ± 8.8% reporting patient's and carer's opinion respectively. Some form of assessment tool was reported by 13 ± 7.3% respondents.Postal survey respondents (n = 31) indicated that decision-making regarding MCA initiation was often or always affected by suitability of medication for dispensing in an MCA by 58% ± 17% of respondents; 74.2% ± 15.4% and 53.3% ± 17.9% of respondents’ decision-making was never or rarely affected by the risk of adverse events and reduced patient autonomy arising from an MCA respectively.ConclusionsProvision of MCAs by pharmacies in England has more than doubled in the past decade. Beyond considering the practicalities of whether an MCA is suitable for a patient, there is limited evidence of pharmacists considering patient choice or risk of adverse events arising from sudden increased adherence prior to initiation.     

探析越鞠丸之肝脾同调

朱丹溪创立的越鞠丸作为一首中医经典方剂,功能行气解郁,总解诸郁,主治“六郁。”目前临床关于本方应用主要含括两方面,一是治疗功能性消化不良等消化系统疾病,所治疾病与脾胃密切相关;二是治疗抑郁症等精神系统疾病,所治疾病与肝亦密切相关。肝脾同调可视为越鞠丸组方之特点,而肝脾之间密切相关,脑肠肽可能是肝脾相关的重要机制,其中5-羟色胺可能是其作用于肝脾的物质基础。故通过研究相关文献,结合越鞠丸创立的时代背景,探究越鞠丸用药规律,联系现代实验研究结果,进一步探讨越鞠丸主治以及肝脾相关理论,以利于提高越鞠丸的临床应用效果。     

蒙药珍宝丸药物血清对雪旺细胞增殖的影响

目的 观察蒙药珍宝丸药物血清对体外培养雪旺细胞增殖的影响.方法 选用新生24 h SD大鼠,取双侧坐骨神经,分离、培养并纯化雪旺细胞,用S -100免疫细胞化学染色法鉴定雪旺细胞,将纯化的雪旺细胞分别用胎牛血清、不同给药剂量大鼠血清、以及不含药大鼠血清培养,并分别于培养的第1天、第4天以及第7天用MTT法观察各组雪旺细胞增殖情况.结果 (1)S - 100免疫染色结果显示纯化后的雪旺细胞纯度为93.8％.(2) MTT法测得培养第7天时高剂量含药血清组OD值明显高于正常剂量含药血清组和不含药大鼠血清组OD值(P＜0.05),而全过程中胎牛血清组OD值明显高于不含药大鼠血清组OD值(P＜0.05).结论 蒙药珍宝丸药物血清在适度条件下可促进雪旺细胞的增殖.     

Insulin Resistance in Polycystic Ovary Syndrome Improved by Chinese Medicine Dingkun Pill(定坤丹):A Randomized Controlled Clinical Trial

Objective: To assess the ef?cacy and safety of the Chinese medicine Dingkun Pill(定坤丹,DKP) on insulin resistance in women with polycystic ovary syndrome(PCOS).Methods: A total of 117 women with PCOS were randomly assigned to Group A(38 women),Group B(40 women),or Group C(39 women) in a randomization sequence with SAS software and a 1:1:1 allocation ratio using random block sizes of 6,and were given 7 g of oral DKP daily(Group A),1 tablet of Diane-35 orally daily(Group B),or 7 g of oral DKP daily plus 1 tablet of Diane-35 orally daily(Group C).Patients took all drugs cyclically for 21 consecutive days,followed by 7 drug-free days.The treatment course for the 3 groups was continued for 3 consecutive months.Oral glucose tolerance tests(OGTT)were performed before treatment and again after 2 and 3 months of therapy,respectively,and homeostasis model assessment for insulin resistance(HOMA-IR) and quantitative insulin sensitivity check index(QUICKI) were calculated.Results: Of 117 women with PCOS,110 completed the entire course of therapy: 35 in Group A,36 in Group B,and 39 in Group C.After treatment,all three groups showed signi?cant decreases in fasting glucose: at1 h glucose decreased signi?cantly in Group A(by 0.5±1.4 mmol/L,P=0.028) and Group C(by 0.5±1.2 mmol/L,P=0.045); while showing a tendency to increase in Group B(by 0.4±1.9 mmol/L,P=0.238).HOMA-IR decreased signi?cantly in Group C [by 0.5(–2.2 to 0.5) m IU mmol/L2,P=0.034].QUICKI was signi?cantly increased in Groups A and C(by 0.009±0.02,P=0.033 and by 0.009±0.027,P=0.049,respectively),while no change was observed in Group B.Repeated-measure ANOVA showed that the absolute changes in all parameters(except for glucose at1 h),including glucose and insulin levels at all time-points during OGTT and in HbA1 c,HOMA-IR,and QUICKI,were not signi?cantly different among the 3 groups after treatment(P0.05).Conclusion: DKP or DKP combined with Diane-35 produce a slight improvement in insulin sensitivity compared with Diane-35 alone in PCOS patients(Trial Registration: Clinical Trials.gov,NCT03264638).